Michael T. Campoli

MDRNA, Inc., represented by Pryor Cashman, closed a registered direct offering raising gross proceeds of $10.5 million on June 12, 2009.

MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference.

The Pryor Cashman team was led by Partners Larry Remmel, Rich Frazer and Stephen Goodman, along with associates Danielle Schechner and Michael Campoli.